investigating the safety, tolerability and efficacy of amorphous calcium carbonate (acc) on the treatment of subjects with crpc

Conditions: Castrate Resistant Prostate Cancer With Bone Metastasis

Summary: studies objectives: to evaluate the safety, tolerability and efficacy of acc given in combination with za or with denosumab as compared to placebo given with za or with denosumab as outline below: * safety and tolerability: * adverse events (aes) and serious aes * safety laboratory measurements * hypercalcemic and hypercalciuric episodes * treatment withdrawal due to aes and overall efficacy: * skeletal related events (sres) * measurable and evaluable disease progression * progression free survival (pfs) * pain assessment via the vas scale


Eligibility criteria:
inclusion criteria: 1. age \> 18 year 2. histologic proof of castrate resistant prostate cancer with bone metastasis 3. systemic steroids are only allowed if needed for hormonal therapy 4. previous radiation therapy must have been completed more than four weeks prior to enrollment into this study, unless subjects are under radiotherapy as a rescue therapy. subjects must have recovered from all side effects. 5. the last dose of chemotherapy must have been completed at least four weeks prior to enrollment into this study, and subjects must have recovered from all side effects. 6. subjects must have a performance status of 0-2 by the ecog scale. 7. subjects must have pretreatment (obtained \ 2,000/μl, platelet count of \> 100,000/μl, wbc \> 3,000/μl, hemoglobin ≥ 10.0 g/dl, serum creatinine \< 1.5 mg/dl, bilirubin \< 1.5 mg/dl, and alt/ast not more than 3x the upper limit of normal (or not more than 5x if the elevation is due to liver metastases). 8. subjects must be normo-calcemic upon study entry. 9. subjects must be vitamin d sufficient upon study entry, which is defined as 25(oh)d serum level \>20 ng/ml (50 nmol/l) according to a document composed by the food and nutrition board of the institute of medicine, usa. if the subject is vitamin d insufficient or deficient, then a loading dose of vitamin d3 will be administered as follows: * if the serum 25(oh)d level is 12-20 ng/ml (30-50 nmol/l) then a loading oral dose of 50,000 iu of vitamin d3 should be administered twice with 3-5 days in between the doses. * if the serum 25(oh)d level is ≤ 12 ng/ml (30 nmol/l), then a loading oral dose of 50,000 iu of vitamin d3 will be administered three times with 3-5 days in between the doses. serum 25(oh)d levels will be checked 1-2 weeks following the last loading. 10. regardless of vitamin d levels, all subjects will receive a daily maintenance dose of 1000 iu vitamin d3, which should be taken in the morning with breakfast. 11. estimated life expectancy of \> 3 months. 12. subjects must be accessible for follow-up. 13. written informed consent will be obtained. exclusion criteria: 1. concurrent treatment with acute anticancer therapy 2. hormonal and corticosteroid therapies for skeletal related events are not allowed 3. sarcoidosis 4. hypercalcemia 5. hypophosphatemia 6. hypoparathyroidism/hyperparathyroidism 7. major surgery within 4 weeks of anticipated inception of amor-1therapy 8. serious intercurrent infections or non-malignant medical illnesses that are uncontrolled or whose control may be jeopardized by the complications of therapy 9. psychiatric disorders rendering subjects incapable of complying with the requirements of the protocol 10. any illness or condition deemed by the investigator to contra-indicate treatment with amor-1 or za or denosumab 11. hypersensitivity to za or denosumab or abiraterone acetate or enzalutamide, or to any bisphosphonates or to any of the following excipients: mannitol and sodium citrate. 12. active cancer treatment except hormonal